Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

CSL Expands Kankakee, Illinois, Manufacturing Operations

03/19/2026
Biotechnology and plasma therapeutics company CSL plans to expand its operations in Kankakee, Illinois. The approximately $1.5 billion project is expected to create 300 jobs.

The investment will include the construction of a new manufacturing facility at the company’s existing campus which will increase its ability to produce plasma-derived therapies. Operations are scheduled to begin by 2031.

"Behind every plasma-derived therapy is a person trying to live a more stable life, and donors who made that therapy possible," said Gordon Naylor, Chief Executive Officer and Managing Director, CSL. "As the need for plasma-derived therapies continues to grow in the U.S. and globally, expanding our Kankakee site further strengthens this key hub in our supply network. We thank our partners in government and our local community for supporting our mission to serve those who require these essential medicines."

CSL Limited specialized in plasma-derived medicines, vaccines, and specialty biotherapies through its major divisions, including CSL Behring, CSL Seqirus, and CSL Vifor. The company’s products are used to treat conditions such as immune deficiencies, bleeding disorders, and influenza.

“CSL's decision to establish a new facility and consolidate its U.S. manufacturing process in Kankakee speaks volumes to Illinois' desirability as a place to do business,” noted Illinois EDC President and CEO Christy George. “Illinois is at the center of commerce and innovation thanks to its elite workforce, strategic location in the heart of the U.S., robust infrastructure, and deeply engaged and collaborative business community, as is evident in Illinois' growing biopharmaceutical ecosystem.”

"CSL's investment underscores the critical role Illinois plays in producing the life-saving therapies patients depend on," added John Conrad, President and CEO of the Illinois Biotechnology Innovation Organization (iBIO). "Our state's combination of scientific talent, manufacturing expertise, and leading research institutions makes Illinois an ideal place for companies to grow advanced biologics manufacturing. Expansions like this help ensure patients around the world have access to the innovative treatments they need."

Exclusive Research